Episode Player
What's happening with specialised commissioning in the NHS?
Pharma Market Access Insights - from Petauri Evidence
Chapters
0:00
Welcome & introductions
5:20
Changes to specialised commissioning
7:20
Implications for industry
12:20
Population based budgeting
18:56
Moving money across a pathway
27:04
Postcode prescribing: local variation vs national variation
38:00
What should companies be doing now around specialised commissioning?
45:12
Who to engage with: Trusts or ICBs?
53:14
Looking to the future - what could specialised commissioning look like in 18 months time?
Pharma Market Access Insights - from Petauri Evidence
What's happening with specialised commissioning in the NHS?
Feb 12, 2024
Season 5
Episode 10
Mtech Access
What’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty?
Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) speaks to David Thorne (Principal Associate, Mtech Access) to explore specialised commissioning in the NHS and what to expect as we head into 2024.
Malcolm Qualie and David Thorne explored:
- Specialised commissioning in the NHS
- The risks and opportunities that devolution to ICBs will bring
- What we can expect to see in the short and longer term
- How industry can support ICB leaders through this transition
- How Pharma, Medtech, and Diagnostics companies, whose products come under specialised commissioning, can manage these risks and uncertainties
Learn more at https://mtechaccess.co.uk/nhs-specialised-commissioning/
This episode first broadcast as a live webinar in Decmeber 2023.
Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence
